Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib re-induction plus donor lymphocyte infusion in relapsed multiple myeloma after allogeneic SCT
2006-005007-34Phase 2Terminated
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by University Medical Center Utrecht. Primary endpoint: CTC toxicity grade 4. Started Oct 2006; status: terminated.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-005007-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005007-34.